10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2017 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
(In Millions) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
Revenues | |||
Product sales | $ 25,662 | 29,953 | 32,151 |
Royalty, contract and other revenues | 445 | 437 | 488 |
Total revenues | 26,107 | 30,390 | 32,639 |
Costs and Expenses | |||
Cost of goods sold | 4,371 | 4,261 | 4,006 |
Research and development expenses | 3,734 | 5,098 | 3,014 |
Selling, general and administrative expenses | 3,878 | 3,398 | 3,426 |
Total costs and expenses | 11,983 | 12,757 | 10,446 |
Income from operations | 14,124 | 17,633 | 22,193 |
Interest expense | (1,118) | (964) | (688) |
Other income (expense), net | 523 | 428 | 154 |
Income before provision for income taxes | 13,529 | 17,097 | 21,659 |
Provision for income taxes | 8,885 | 3,609 | 3,553 |
Net income | 4,644 | 13,488 | 18,106 |
Net income (loss) attributable to noncontrolling interest | 16 | (13) | (2) |
Net income attributable to Gilead | 4,628 | 13,501 | 18,108 |
Net income per share attributable to Gilead common stockholders - basic | 3.54 | 10.08 | 12.37 |
Shares used in per share calculation - basic | 1,307 | 1,339 | 1,464 |
Net income per share attributable to Gilead common stockholders - diluted | 3.51 | 9.94 | 11.91 |
Shares used in per share calculation - diluted | 1,319 | 1,358 | 1,521 |
Cash dividends declared per share | 2.08 | 1.84 | 1.29 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2017 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
Net income | $ 4,644 | 13,488 | 18,106 |
Other Comprehensive Income (Loss) | |||
Net foreign currency translation gain (loss), net of tax | (47) | 177 | 9 |
Available-for-sale Securities | |||
Net unrealized gain (loss), net of tax impact of $6, $19 and $(17), respectively | 218 | 7 | (29) |
Reclassifications to net income, net of tax impact of $(9), $0 and $1, respectively | (8) | (7) | 1 |
Net change | 210 | 0 | (28) |
Cash Flow Hedges | |||
Net unrealized gain (loss), net of tax impact of $(11), $0 and $21, respectively | (304) | 5 | 389 |
Reclassification to net income, net of tax impact of $0, $(8) and $(19), respectively | 28 | 8 | (583) |
Net change | (276) | 13 | (194) |
Other comprehensive income (loss) | (113) | 190 | (213) |
Comprehensive income | 4,531 | 13,678 | 17,893 |
Comprehensive income (loss) attributable to noncontrolling interest | 16 | (13) | (2) |
Comprehensive income attributable to Gilead | 4,515 | 13,691 | 17,895 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2017 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | |||
(In Millions, except shares in actual) | |||
12 Months Ended | 12 Months Ended | 12 Months Ended | |
Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
Operating Activities: | |||
Net income | $ 4,644 | 13,488 | 18,106 |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation expense | 233 | 177 | 161 |
Amortization expense | 1,053 | 981 | 937 |
Stock-based compensation expense | 638 | 380 | 382 |
Deferred income taxes | (82) | (119) | (393) |
In-process research and development impairment | 0 | 432 | 0 |
Other | 304 | 162 | 562 |
Changes in operating assets and liabilities: | |||
Accounts receivable, net | 754 | 1,192 | (1,397) |
Inventories | (253) | (488) | (855) |
Prepaid expenses and other | 358 | (520) | (90) |
Accounts payable | (430) | 47 | 226 |
Income taxes payable | 5,497 | 1,010 | 269 |
Accrued liabilities | (818) | 305 | 3,342 |
Net cash provided by operating activities | 11,898 | 17,047 | 21,250 |
Investing Activities: | |||
Purchases of marketable securities | (23,314) | (25,619) | (17,239) |
Proceeds from sales of marketable securities | 10,440 | 13,039 | 4,792 |
Proceeds from maturities of marketable securities | 7,821 | 1,700 | 719 |
Other investments | 0 | (357) | 0 |
Acquisitions, net of cash acquired | (10,426) | 0 | 0 |
Capital expenditures | (590) | (748) | (747) |
Net cash used in investing activities | (16,069) | (11,985) | (12,475) |
Financing Activities: | |||
Proceeds from debt financing, net of issuance costs | 8,985 | 5,293 | 9,902 |
Proceeds from convertible note hedges | 0 | 956 | 784 |
Proceeds from issuances of common stock | 234 | 208 | 319 |
Repurchases of common stock | (954) | (11,001) | (10,002) |
Repayments of debt and other obligations | (1,811) | (1,981) | (997) |
Payments to settle warrants | 0 | (469) | (3,865) |
Payment of dividends | (2,731) | (2,455) | (1,874) |
Other | (330) | (276) | (151) |
Net cash provided by (used in) financing activities | 3,393 | (9,725) | (5,884) |
Effect of exchange rate changes on cash and cash equivalents | 137 | 41 | (67) |
Net change in cash and cash equivalents | (641) | (4,622) | 2,824 |
Cash and cash equivalents at beginning of period | 8,229 | 12,851 | |
Cash and cash equivalents at end of period | 7,588 | 8,229 | 12,851 |
Supplemental disclosure of cash flow information: | |||
Interest paid, net of amounts capitalized | 1,038 | 885 | 529 |
Income taxes paid | 3,342 | 2,436 | 3,137 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
GILEAD SCIENCES, INC. | ||
Ticker: GILD Fiscal Year: 2017 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2017 10-K (Filed: Feb 27, 2018) | ||
(In Millions, except shares in actual) | ||
As of | As of | |
Dec 31, 2017 | Dec 31, 2016 | |
Assets | ||
Current assets | ||
Cash and cash equivalents | $ 7,588 | 8,229 |
Short-term marketable securities | 17,922 | 3,666 |
Accounts receivable, net of allowances of $455 at December 31, 2017 and $763 at December 31, 2016 | 3,851 | 4,514 |
Inventories | 801 | 1,587 |
Prepaid and other current assets | 1,661 | 1,592 |
Total current assets | 31,823 | 19,588 |
Property, plant and equipment, net | 3,295 | 2,865 |
Long-term marketable securities | 11,184 | 20,485 |
Intangible assets, net | 17,100 | 8,971 |
Goodwill | 4,159 | 1,172 |
Other long-term assets | 2,722 | 3,896 |
Total assets | 70,283 | 56,977 |
Liabilities and Stockholders Equity | ||
Current liabilities | ||
Accounts payable | 814 | 1,206 |
Accrued government and other rebates | 4,704 | 5,021 |
Other accrued liabilities | 3,370 | 2,991 |
Current portion of long-term debt and other obligations, net | 2,747 | 0 |
Total current liabilities | 11,635 | 9,218 |
Long-term debt, net | 30,795 | 26,346 |
Long-term income taxes payable | 6,794 | 1,753 |
Other long-term obligations | 558 | 297 |
Commitments and contingencies (Note 12) | ||
Stockholders' Equity | ||
Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
Common stock, par value $0.001 per share; shares authorized of 5,600 at December 31, 2017 and December 31, 2016; shares issued and outstanding of 1,308 at December 31, 2017 and 1,310 at December 31, 2016 | 1 | 1 |
Additional paid-in capital | 1,264 | 454 |
Accumulated other comprehensive income | 165 | 278 |
Retained earnings | 19,012 | 18,154 |
Total Gilead stockholders equity | 20,442 | 18,887 |
Noncontrolling interest | 59 | 476 |
Total stockholders equity | 20,501 | 19,363 |
Total liabilities and stockholders equity | 70,283 | 56,977 |
External Links | |
GILEAD SCIENCES, INC. (GILD) Fiscal Year 2017 | |
Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |